NIH Disclosure Of Outside Activities Differs From Pfizer Report, House Cmte. Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
House Commerce Committee identifies 100 instances where drug companies reported consulting arrangements and the National Institutes of Health did not disclose those arrangements. In an effort to place "NIH ethics issues in context," the committee is requesting FDA and 14 other agencies submit lists of outside compensation.
You may also be interested in...
NIMH Senior Staffer Charged With Accepting Improper Payments From Pfizer
Charges relate to undisclosed consulting gig, U.S. attorney says.
NIMH Senior Staffer Charged With Accepting Improper Payments From Pfizer
Charges relate to undisclosed consulting gig, U.S. attorney says.
BIO Top Job May Go To Rep. Greenwood
Oversight Subcommittee chairman confirms he is considering leaving Congress to pursue a new opportunity, but says he will have no further comment until he makes a decision "in the very near future." Greenwood has been among most active legislators on pharmaceutical issues, and has worked with BIO on stem cell and human subject protection proposals.